Pioneering designs for recombinant coagulation factors

Area of Science:

• Biotechnology
• Hematology
• Pharmacology

Background:

• Coagulation factor replacement therapy is crucial for managing bleeding disorders like hemophilia A, B, and von Willebrand disease.
• Recombinant DNA technology enables modification of coagulation factors to improve therapeutic properties.
• CSL Behring is developing novel recombinant proteins to enhance treatment efficacy and patient convenience.

Purpose of the Study:

• To develop novel recombinant coagulation factor therapies with improved pharmacokinetic profiles.
• To extend the half-life of activated recombinant factor VII (rFVIIa) and recombinant factor IX (rFIX) through albumin fusion.
• To create a more stable recombinant factor VIII (CSL627) with enhanced von Willebrand factor binding.

Main Methods:

• Development of albumin fusion proteins (rVIIa-FP and rIX-FP) for extended half-life.
• Preclinical evaluation of pharmacokinetic properties and hemostatic efficacy.
• Design and characterization of a recombinant single-chain factor VIII protein (CSL627).

Main Results:

• Recombinant albumin fusion proteins (rVIIa-FP, rIX-FP) demonstrated improved pharmacokinetics, including extended half-life.
• Hemostatic efficacy was preserved in preclinical studies of the fusion proteins.
• CSL627 exhibits enhanced stability and high von Willebrand factor affinity.

Conclusions:

• Novel recombinant proteins, rVIIa-FP, rIX-FP, and CSL627, show potential for improved management of bleeding disorders.
• Extended half-life and enhanced stability may lead to less frequent dosing for patients.
• Further clinical evaluation is necessary to define the utility of these advanced therapies.